Evotec SE — Board/Management Information 2001

Apr 18, 2001

News Details

Ad-hoc | 18 April 2001 13:20

Ad hoc-Service: EVOTEC BioSystems AG english

Ad hoc announcement processed and transmitted by DGAP. The issuer has the sole responsibility of this announcement. ——————————————————————————– EVOTEC OAI Appointment of new Chief Executive Officer Evotec OAI today announces key management changes following the successful integration of EVOTEC BioSystems AG and Oxford Asymmetry International. With effect from June 30, 2001, Jörn Aldag, the group’s Chief Financial Officer, will become President and Chief Executive Officer of Evotec OAI. The company is in the process of seeking a new Finance Director. Dr Karsten Henco, currently CEO, and Dr Edwin Moses, currently President, will resign from their positions in order to join the Supervisory Board of Evotec OAI. Both will act as consultants to the Group’s management. Dr Henco will continue to focus on his duties as a member of the Scientific Advisory Board of Evotec OAI. Dr Timm Jessen, Chief Scientific Officer, and Dr Mario Polywka. Chief Operating Officer, will continue in their respective positions. Dr Jessen’s responsibilities include the development of Evotec OAI’s biology and chemistry sciences as well as overseeing major technology partnerships. Dr Polywka will be responsible for Evotec OAI’s operations. He will also continue as head of Evotec OAI’s Oxford, UK, site. The Group is also pleased to announce the appointment of Sean Marrett as Commercial Director, heading the group’s Business Development. Dr Marrett joined Evotec OAI in April 2001 from GlaxoSmithKline, where he was Director, New Product Development US Operating Division. Dr Pol Bamelis, Chief Scientific Officer and member of the Management Board (Vorstand) of Bayer AG, will also Join the Supervisory Board, with effect from May 1, 2001. Under Dr Bamelis tenure Bayer staged multi-million dollar collaborations with leading biotechnology companies and Evotec OAI will benefit from his great experience in the pharmaceutical industry. Roland Oetker and Prof. Hans Jürgen Quadbeck-Seeger will step down from the Supervisory Board. end of ad hoc announcement, (c) DGAP 18.04.2001 Issuer’s information/explanation remarks concerning this ad hoc announcement: Jörn Aldag commented: “The changes announced today are a continuation of our plans at the time of the merger between Evotec and OAI last year. Karsten Henco and Edwin Moses have played a hugely important role in building up this company and ensuring that its merger has been such a success. I am delighted that Evotec OAI will continue to benefit from their invaluable support and experience in the next stages of our rapid development as a leader in the discovery and development of new drugs. I would also like to pay tribute to Roland Oetker and Prof Quadbeck- Seeger for their invaluable support over many years.” Karsten Henco added: “Evotec OAI is now beginning an exciting new phase of growth and development, and it has a first-class management team to take it forward. I am delighted to have the opportunity to play a role in the Company’s continued success.” Edwin Moses says: “We achieved our internal milestones for the integration of EVOTEC and OAI very quickly. In addition, we have recently closed our first combined research contract with a biotechnology company. I am pleased to continue to oversee Evotec OAI’s future development as a member of the Supervisory Board.” EVOTEC BioSystems AG Anne Hennecke, Investor Relations Phone: +49-40-56081286 Fax: +49-40-56081333 E-mail: anne.hennecke@evotecoai.com ——————————————————————————– WKN: 566480; Index: NEMAX-50 Listed: Neuer Markt in Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart 181320 Apr 01